New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
08:03 EDTSLPSimulations Plus announces 'success' in COX-2, COX-1 drug design project
Simulations Plus announced that its second new chemical entity initiative, which involved using Simulations Plus software to design molecules to inhibit COX-2, has been a success as determined by synthesis and testing by a third-party lab. Three of the four molecules it has designed are potent inhibitors of both cyclooxygenase-2 and COX-1 enzymes. The fourth inhibits COX-2 but only weakly inhibits COX-1. The company said, "This project was more challenging than the malaria NCE project we completed two years ago because this time our goal was to inhibit two targets with a single molecule while also providing good absorption, distribution, metabolism, excretion, and toxicity properties."
News For SLP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
14:56 EDTSLPSimulations Plus management to meet with Sidoti
Meeting to be held in Minneapolis on December 10 hosted by Sidoti.
December 3, 2014
08:44 EDTSLPSimulations Plus reports Q1 preliminary revenue $3.96M, one estimate $2.89M
CFO John Kneisel said, “We are pleased to report that with our acquisition of Cognigen Corporation at the beginning of 1QFY15, our revenues for this first quarter set a new record of $3.96M, an increase of 50% from $2.64M in 1QFY14." CEO Walt Woltosz added: “The acquisition of Cognigen Corporation has started off our fiscal year with a significant jump in revenues over the first quarter of last fiscal year...The nature of our Cognigen division’s business, which is focused on consulting studies, requires estimation of percentage completion on many contracts in order to provide these preliminary revenues. Final revenues will be provided when we file our quarterly report on Form 10-Q in January.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use